The study of the rocuronium-sugammadex complex: particularly, study on safety to people with renal dysfunction about rocuronium-sugammadex complex

The study of the rocuronium-sugammadex complex: particularly, study on safety to people with renal dysfunction about rocuronium-sugammadex complex - The study of the rocuronium-sugammadex complex: particularly, study on safety to people with renal dysfunction about rocuronium-sugammadex complex

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028642

Enrollment

Registered

2017-08-11

Start date

2013-05-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal dysfunction

Interventions

Interventions:Under general anesthesia Sugammadex:2~4mg/kg intravenous injection Control:county

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Renal dysfunction group:eGFR lower 15 Normal group:eGFR over 90

Exclusion criteria

Exclusion criteria: Over 15 eGFR and lower 90 eGFR

Design outcomes

Primary

Measure	Time frame
Under general anesthesia, with a mucle relaxation monitor, we perform an intravenous injection of sugammadex from a muscle relaxation state and evaluate a difference at muscle relaxation recovery time with renal dysfunction people group and the normal group required for Train of Four 100% recovery	—

Countries

Japan

Contacts

Public ContactAkihiko Maeyama

Saitama Medical University Hospital Department of Anesthesiology

maeyamaakihiko@gmail.com049-276-1271

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026